Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes

Thomas Pearson1, Laurie Kopin

  • 1Department of Community and Preventive Medicine, University of Rochester Medical Center, NY, USA.

Preventive Cardiology
|November 8, 2003
PubMed

Insights

Improving patient compliance with lifestyle changes and lipid-modifying therapies is crucial for managing abnormal lipid levels and reducing cardiovascular disease mortality. Addressing this treatment gap requires patient education and physician engagement.

Area of Science:

  • Cardiology
  • Public Health

Background:

  • Cardiovascular disease (CVD) poses a significant societal burden, with abnormal lipid levels contributing to increased coronary heart disease (CHD) mortality.
  • Inadequate management of lipid levels represents a critical treatment gap, impacting primary and secondary prevention efforts.

Purpose of the Study:

  • To highlight the importance of patient compliance in lipid management for reducing cardiovascular mortality.
  • To identify strategies for improving adherence to therapeutic lifestyle changes and lipid-modifying therapies.

Main Methods:

  • Literature review and synthesis of current understanding regarding patient compliance in lipid management.
  • Analysis of factors contributing to poor adherence and potential interventions.

Main Results:

  • Poor patient compliance with lifestyle modifications and lipid-lowering medications is a primary driver of suboptimal lipid management.
  • Effective strategies include patient education, physician proactivity, and the use of well-tolerated, convenient therapies.

Conclusions:

  • Improving compliance is essential to translate clinical trial benefits of lipid management to the general population and reduce CHD mortality.
  • A proactive, collaborative approach involving patients and physicians, alongside optimized therapeutic options, is key to overcoming this challenge.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...